We further validated in bladder cancer Umuc-3 and 5637 cells that phosphorylation of Bcl2, Bad, and FoxO1 was consistently repressed by PPARγ agonist rosiglitazone, but enhanced by the inverse agonist T0070907. Here, FOXO1 is linked to urinary bladder cancer.